Lipocine Hit By Investor With Testosterone Drug 'Scheme' Suit
By Rose Krebs ( February 21, 2019, 9:23 PM EST) -- Specialty pharmaceutical company Lipocine Inc. and some of its officers were hit with a derivative suit in Delaware Chancery Court over claims they engaged in a "scheme" to mislead investors by failing to reveal issues with the company's testosterone pill....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.